Skip to main content
Erschienen in: Supportive Care in Cancer 1/2013

01.01.2013 | Original Article

A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer

verfasst von: Gregory M. M. Videtic, Chandana A. Reddy, Lisa Sorenson

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The study seeks to prospectively evaluate pulmonary function and quality of life (QOL) in medically inoperable early-stage lung cancer patients undergoing stereotactic body radiotherapy (SBRT).

Methods

QOL was assessed by Functional Assessment of Cancer Therapy-Lung (FACT-L) and the UCSD Medical Center Pulmonary Rehabilitation Program Shortness-of-Breath Questionnaire before and after SBRT at 6 weeks, and every 3 months until 12 months. Clinical investigations included pulmonary functions tests and blood profile and chemistries. SBRT was delivered on a Novalis/BrainLab system.

Results

Twenty-one analyzable patients were enrolled between July 2008 to April 2009. There were 12 males (52.4 %), 14 patients (66.7 %) had Zubrod performance 1, the median age was 77 years (range 61–90), and 87 % was inoperable because of pulmonary impairment. Median tumor size was 3.0 cm (range 1–4.6). Median follow-up was 17.6 months. One-year local control was 100 %. There were no significant changes in the median total FACT-L scores: 109 at baseline compared to 112 at 1 year. Mean UCSD scores were not significant for the year. No significant changes in mean baseline compared to 1-year FEV1 and 6-min walks as % predicted were seen but a significant DLCO change (p = 0.012) was attributed to the decreased range in the standard deviations.

Conclusions

Following SBRT, QOL is not significantly degraded. Pulmonary function is likewise not significantly impaired overall. Along with favorable survival results, these findings confirm that SBRT is appropriate for this patient population.
Literatur
1.
Zurück zum Zitat Hansen HH (2009) Introduction. In: Hansen HH (ed) Lung Cancer Therapy Annual 6. Informa Health Care, New York, pp 1–6 Hansen HH (2009) Introduction. In: Hansen HH (ed) Lung Cancer Therapy Annual 6. Informa Health Care, New York, pp 1–6
2.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRef
3.
Zurück zum Zitat Hansen HH (2009) Histopathology. In: Hansen HH (ed) Lung cancer therapy annual 6. Informa Health Care, New York, pp 45–56 Hansen HH (2009) Histopathology. In: Hansen HH (ed) Lung cancer therapy annual 6. Informa Health Care, New York, pp 45–56
4.
Zurück zum Zitat Juettner-Smolle FM, Lindenmann J, Matzi V, Neubock N (2010) Resection in stage I/II non-small cell lung cancer. In: Heide J et al (eds) Controversies in the treatment of lung cancer. Karger, Basel, pp 71–77 Juettner-Smolle FM, Lindenmann J, Matzi V, Neubock N (2010) Resection in stage I/II non-small cell lung cancer. In: Heide J et al (eds) Controversies in the treatment of lung cancer. Karger, Basel, pp 71–77
5.
Zurück zum Zitat Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, Webb WR, Stewart AK (2005) Patterns of surgical care of lung cancer patients. Ann Thorac Surg 80:2051–2056PubMedCrossRef Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, Webb WR, Stewart AK (2005) Patterns of surgical care of lung cancer patients. Ann Thorac Surg 80:2051–2056PubMedCrossRef
6.
Zurück zum Zitat Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615–622PubMedCrossRef Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615–622PubMedCrossRef
7.
Zurück zum Zitat Nyman J, Johansson KA, Hultén U (2006) Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer—mature results for medically inoperable patients. Lung Cancer 51:97–103PubMedCrossRef Nyman J, Johansson KA, Hultén U (2006) Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer—mature results for medically inoperable patients. Lung Cancer 51:97–103PubMedCrossRef
8.
Zurück zum Zitat Lax I, Blomgren H, Näslund I, Svanström R (1994) Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 33:677–683PubMedCrossRef Lax I, Blomgren H, Näslund I, Svanström R (1994) Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 33:677–683PubMedCrossRef
9.
Zurück zum Zitat Stephans KL, Djemil T, Reddy CA et al (2009) A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol 4:976–982PubMedCrossRef Stephans KL, Djemil T, Reddy CA et al (2009) A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol 4:976–982PubMedCrossRef
10.
Zurück zum Zitat Haasbeek CJ, Lagerwaard FJ, de Jaeger K, Slotman BJ, Senan S (2009) Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. Cancer 115:587–594PubMedCrossRef Haasbeek CJ, Lagerwaard FJ, de Jaeger K, Slotman BJ, Senan S (2009) Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. Cancer 115:587–594PubMedCrossRef
11.
Zurück zum Zitat Haasbeek CJ, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S (2010) Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer 116:406–414PubMedCrossRef Haasbeek CJ, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S (2010) Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer 116:406–414PubMedCrossRef
12.
Zurück zum Zitat Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, Timmerman RD, McGarry RC (2007) FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 56:229–234PubMedCrossRef Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, Timmerman RD, McGarry RC (2007) FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 56:229–234PubMedCrossRef
13.
Zurück zum Zitat Onishi H, Shirato H, Nagata Y et al (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2:S94–S100PubMedCrossRef Onishi H, Shirato H, Nagata Y et al (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2:S94–S100PubMedCrossRef
14.
Zurück zum Zitat Chang JY, Roth JA (2007) Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin 17:251–259PubMedCrossRef Chang JY, Roth JA (2007) Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin 17:251–259PubMedCrossRef
15.
Zurück zum Zitat Timmerman R, Papiez L, McGarry R et al (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955PubMedCrossRef Timmerman R, Papiez L, McGarry R et al (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955PubMedCrossRef
16.
Zurück zum Zitat Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833–4839PubMedCrossRef Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833–4839PubMedCrossRef
17.
Zurück zum Zitat Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–1076PubMedCrossRef Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–1076PubMedCrossRef
18.
Zurück zum Zitat Langendijk JA, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Slotman BJ, Wouters EF (2002) Quality of life after curative radiotherapy in Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 53:847–853PubMedCrossRef Langendijk JA, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Slotman BJ, Wouters EF (2002) Quality of life after curative radiotherapy in Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 53:847–853PubMedCrossRef
19.
Zurück zum Zitat van der Voort van Zyp NC, Prévost JB, van der Holt B, Braat C, van Klaveren RJ, Pattynama PM, Levendag PC, Nuyttens JJ (2010) Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 77:31–37PubMedCrossRef van der Voort van Zyp NC, Prévost JB, van der Holt B, Braat C, van Klaveren RJ, Pattynama PM, Levendag PC, Nuyttens JJ (2010) Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 77:31–37PubMedCrossRef
20.
Zurück zum Zitat Lung (2002) In: Greene FL et al. (eds) AJCC cancer staging handbook, 6th edn. Springer, New York, pp 191–204 Lung (2002) In: Greene FL et al. (eds) AJCC cancer staging handbook, 6th edn. Springer, New York, pp 191–204
21.
Zurück zum Zitat Videtic GM, Stephans K, Reddy C, Gajdos S, Kolar M, Clouser E, Djemil T (2010) Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control. Int J Radiat Oncol Biol Phys 77:344–349PubMedCrossRef Videtic GM, Stephans K, Reddy C, Gajdos S, Kolar M, Clouser E, Djemil T (2010) Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control. Int J Radiat Oncol Biol Phys 77:344–349PubMedCrossRef
22.
Zurück zum Zitat Stephans KL, Djemil T, Reddy CA et al (2009) Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 4:838–844PubMedCrossRef Stephans KL, Djemil T, Reddy CA et al (2009) Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 4:838–844PubMedCrossRef
23.
Zurück zum Zitat Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S (2008) Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:685–692PubMedCrossRef Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S (2008) Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:685–692PubMedCrossRef
24.
Zurück zum Zitat Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P (1995) Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199–220PubMedCrossRef Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P (1995) Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199–220PubMedCrossRef
25.
Zurück zum Zitat Henoch I, Bergman B, Gustafsson M, Gaston-Johansson F, Danielson E (2007) The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer. J Pain Symptom Manag 34:370–379CrossRef Henoch I, Bergman B, Gustafsson M, Gaston-Johansson F, Danielson E (2007) The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer. J Pain Symptom Manag 34:370–379CrossRef
26.
Zurück zum Zitat Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM (1998) Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 113:619–624PubMedCrossRef Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM (1998) Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 113:619–624PubMedCrossRef
28.
Zurück zum Zitat Mohan A, Mohan C, Pathak AK, Pandey RM, Guleria R (2007) Impact of chronic obstructive pulmonary disease on respiratory status and quality of life in newly diagnosed patients with lung cancer. Respirology 12:240–247PubMedCrossRef Mohan A, Mohan C, Pathak AK, Pandey RM, Guleria R (2007) Impact of chronic obstructive pulmonary disease on respiratory status and quality of life in newly diagnosed patients with lung cancer. Respirology 12:240–247PubMedCrossRef
29.
Zurück zum Zitat Lima LN, da Silva RA, Gross JL, Deheinzelin D, Negri EM (2009) Assessment of pulmonary function and quality of life in patients submitted to pulmonary resection for cancer. J Bras Pneumol 35:521–528PubMedCrossRef Lima LN, da Silva RA, Gross JL, Deheinzelin D, Negri EM (2009) Assessment of pulmonary function and quality of life in patients submitted to pulmonary resection for cancer. J Bras Pneumol 35:521–528PubMedCrossRef
30.
Zurück zum Zitat Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed
31.
Zurück zum Zitat Sorenson LM, Reddy C, Videtic G (2010) Lessons learned from a prospective study of quality of life in lung cancer patients undergoing stereotactic body radiotherapy: the earlier, the better! Int J Radiat Oncol Biol Phys 78(suppl):S608–S609CrossRef Sorenson LM, Reddy C, Videtic G (2010) Lessons learned from a prospective study of quality of life in lung cancer patients undergoing stereotactic body radiotherapy: the earlier, the better! Int J Radiat Oncol Biol Phys 78(suppl):S608–S609CrossRef
Metadaten
Titel
A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer
verfasst von
Gregory M. M. Videtic
Chandana A. Reddy
Lisa Sorenson
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1513-9

Weitere Artikel der Ausgabe 1/2013

Supportive Care in Cancer 1/2013 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.